Monitor for safety and PK data from the SAD portion in H1 2027, followed by the interim Phase 2 activity readout in H2 2027. The first-in-human data is the next binary catalyst for the stock.
Price Chart
Executive Summary
Korro Bio dosed the first cohort of healthy volunteers in its Phase 1/2 ANCHOR trial for KRRO-121, a GalNAc-conjugated RNA-editing oligonucleotide for hyperammonemia in urea cycle disorders and hepatic encephalopathy. This is an early clinical milestone with no safety or efficacy data yet, moving the pipeline from preclinical to clinical stage. The next catalyst is UCD patient dosing expected in H1 2027 with an interim readout in H2 2027.
Key Facts
- First cohort dosed with a single 2 mg/kg dose of KRRO-121 in healthy volunteers in Australia.
- ANCHOR is a global Phase 1/2 trial with Part 1 (SAD/MAD in up to 50 healthy volunteers) and Part 2 (Phase 2 in up to 15 UCD patients).
- UCD patient dosing expected to start in H1 2027, with an interim clinical readout in H2 2027.
- KRRO-121 is designed as a pan-UCD treatment using a synthetic rescue approach to generate glutamine synthetase protein.
Financial Impact
No financial data disclosed in the filing. Pre-revenue clinical-stage biotech; the event is a clinical milestone with no revenue impact.
Risk Factors
- No safety or efficacy data yet; early clinical data may not replicate preclinical results.
- Long timeline to next catalyst (UCD patient dosing in H1 2027) with no interim data until H2 2027.
- Competing therapies exist for UCD and HE indications; KRRO-121 is unproven in humans.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-414118 |
| Document: krro-ex99_1.htm | 0001193125-26-414118 |
| Document: 0001193125-26-414118-index-headers.html | 0001193125-26-414118 |
| Document: 0001193125-26-414118-index.html | 0001193125-26-414118 |
| Document: 0001193125-26-414118.txt | 0001193125-26-414118 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | Insider Buy | $12.46 | awaiting T+1 | — | $12.02 (−3.53%) |
Oct 22, 2026 4d ago | 8-K | $12.05 $11.98 | ▼ −0.58% | ▼ −0.06% | $12.02 (−0.25%) |
Oct 16, 2026 10d ago | Press Release | $8.91 $9.44 | ▲ +5.95% | ▲ +5.61% | $12.02 (+34.90%) |
Oct 5, 2026 21d ago | 8-K | $9.76 $10.49 | ▲ +7.48% | ▲ +7.72% | $12.02 (+23.16%) |
Oct 5, 2026 21d ago | Press Release | $9.76 $10.49 | ▲ +7.48% | ▲ +7.72% | $12.02 (+23.16%) |
Sep 15, 2026 5w ago | Insider Cluster | $13.83 $11.80 | ▼ −14.68% | ▼ −15.81% | $12.02 (−13.09%) |
Aug 13, 2026 10w ago | Insider Cluster | $13.29 $13.28 | ▼ −0.08% | ▲ +0.12% | $12.02 (−9.56%) |
Aug 6, 2026 11w ago | 8-K | $12.12 $13.25 | ▲ +9.32% | ▲ +8.71% | $12.02 (−0.83%) |
Jul 9, 2026 15w ago | Institutional Cluster | $14.30 $14.56 | ▲ +1.82% | ▲ +1.39% | $12.02 (−15.94%) |
Jun 24, 2026 17w ago | Insider Cluster | $12.17 $12.70 | ▼ −4.36% | ▼ −5.08% | $12.02 (+1.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers